Twinlab Consolidated Holdings, INC
Quarterly Earnings (10-Q)
OTC.Pink
Twinlab Consolidated Holdings reports significant revenue decline, ongoing losses, and critical debt defaults, raising substantial doubt about its ability to continue as a going concern.
Worse than expected
Capital raise
Delay expected
OTC.Pink
10-Q: Twinlab Consolidated Holdings Reports Mixed Results in Q2 2024 Amidst Ongoing Financial Challenges
Twinlab Consolidated Holdings experienced a slight increase in net sales but continued to face significant financial challenges, including a substantial accumulated deficit and working capital deficiency, as detailed in their Q2 2024 report.
Worse than expected
Delay expected
Capital raise
OTC.Pink
Twinlab Consolidated Holdings experienced a decrease in net sales and continues to face substantial doubt about its ability to continue as a going concern, as highlighted in its Q1 2024 report.
Worse than expected
Capital raise
Annual Reports (10-K)
OTC.Pink
Twinlab Consolidated Holdings, Inc. reports significant operating losses, a substantial accumulated deficit, and debt defaults, raising substantial doubt about its ability to continue as a going concern.
Capital raise
Worse than expected
OTC.Pink
Twinlab Consolidated Holdings reports a net loss of $13.7 million for 2023, impacted by production issues and reduced demand, while also ceasing operations of its NutraScience Labs business.
Capital raise
Worse than expected
Insider Trading (Form 4)
OTC.Pink
B. Thomas Golisano, a director and 10% owner of Twinlab Consolidated Holdings, Inc., sold his membership interest in Akretive Holdings, LLC, which held a significant amount of Twinlab's common stock.